Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / @xirurgi_2025 / @xirurgi_2025 - 881 - файл
.pdf
9 Pancreatic Neuroendocrine Tumors (pNETs)
22. Heaphy CM, de Wilde RF, Jiao Y, etal. Altered telomeres in tumors with ATRX and DAXX
mutations. Science. 2011;333:425.
23. Singh R, Basturk O, Klimstra DS, etal. Lipid-rich variant of pancreatic endocrine neoplasms.
Am J Surg Pathol. 2006;30:194–200.
24. Marinoni I, Kurrer AS, Vassella E, etal. Loss of DAXX and ATRX are associated with chro-
mosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Gastroenterology. 2014;146:453–60.
25. Klimsta DS, Armold R, Capella C, etal. Neuroendocrine neoplasms of the pancreas. In:
Bosman F, Carneiro F, Hruban RH, etal., editors. WHO classication of tumours of the diges-
tive system. Lyon: IARC Press; 2010. p.322–6.
26. Rindi G, Kloppel G, Alhman H, etal. TNM staging of foregut (neuro)endocrine tumors: a
consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.
27. Exocrine and endocrine pancreas. AJCC cancer staging manual. NewYork, NY: Springer;
2010. p.241–9.
28. Ellison TA, Wolfgang CL, Shi C, etal. A single institution’s 26-year experience with nonfunc-
tional pancreatic neuroendocrine tumors: a validation of current staging systems and a new
prognostic nomogram. Ann Surg. 2014;259:204–12.
29. Liu TC, Hamilton N, Hawkins W, et al. Comparison of WHO classications (2004, 2010),
the Hochwald grading system, and AJCC and ENETS staging systems in predicting progno-
sis inlocoregional well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol.
2013;37:853–9.
30. Rindi G, Falconi M, Klersy C, etal. TNM staging of neoplasms of the endocrine pancreas:
results from a large international cohort study. J Natl Cancer Inst. 2012;104:764–77.
31. Sakurai A, Katai M, Yamashita K, etal. Long term follow-up of patients with multiple endo-
crine neoplasia type 1. Endocr J. 2007;54:295–302.
32. Davì MV, Boninsegna L, Dalle Carbonare L, etal. Presentation and outcome of pancreaticoduo-
denal endocrine tumors in multiple endocrine neoplasia type 1 syndrome. Neuroendocrinology.
2011;94:58–65.
33. Broder LE, Carter SK.Pancreatic islet cell carcinoma. I.Clinical features of 52 patients. Ann
Intern Med. 1973;79:101–7.
34. Cubilla AL, Hajdu SI.Islet cell carcinoma of the pancreas. Arch Pathol. 1975;99:204–7.
35. La Rosa S, Klersy C, Uccella S, etal. Improved histologic and clinicopathologic criteria for
prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30–40.
36. Schmitt AM, Anlauf M, Rousson V, WHO, etal. Criteria and CK19 are reliable prognostic
markers in pancreatic endocrine tumors. Am J Surg Pathol. 2004;2007(31):1677–82.
37. Zhu L, Domenico DR, Howard JM.Metastatic pancreatic neuroendocrine carcinoma causing
Cushing’s syndrome. ACTH secretion by metastases 3 years after resection of nonfunctioning
primary cancer. Int J Pancreatol. 1996;19:205–8.
38. Milanesi A, Yu R, Geller SA, et al. Concurrent primary hyperparathyroidism and humoral
hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1. Pancreas.
2011;40:634–7.
39. Miehle K, Tannapfel A, Lamesch P, etal. Pancreatic neuroendocrine tumor with ectopic adre-
nocorticotropin production upon second recurrence. J Clin Endocrinol Metab. 2004;89:3731–6.
40. Heik SCW, Klöppel G, Krone W, etal. Hypoglykämie durch Insulinom bei Diabetes mellitus.
Dtsch Med Wochenschr. 1988;113:1714–7.
41. Mann JR, Rayner PH, Gourevitch A.Insulinoma in childhood. Arch Dis Child. 1969;44:435–42.
42. Lo CY, Lam KY, Kung AW, etal. Pancreatic insulinomas. A 15-year experience. Arch Surg.
1997;132:926–30.
43. Sempoux C, Guiot Y, Dahan K, etal. The focal form of persistent hyperinsulinemic hypogly-
cemia of infancy: morphological and molecular studies show structural and functional differ-
ences with insulinoma. Diabetes. 2003;52:784–94.
44. Reinecke-Lüthge A, Koschoreck F, Klöppel G.The molecular basis of persistent hyperinsulin-
emic hypoglycemia of infancy and its pathologic substrates. Virchows Arch. 2000;436:1–5.
45. Keller A, Stone AM, Valderrama E, etal. Pancreatic nesidioblastosis in adults. Report of a
patient with hyperinsulinemic hypoglycemia. Am J Surg. 1983;145:412–6.
149
150
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
A. Sanguinetti et al.
46. Anlauf M, Wieben D, Perren A, etal. Persistent hyperinsulinemic hypoglycemia in 15 adults
with diffuse nesidioblastosis: diagnostic criteria, incidence and characterization of β-cell
changes. Am J Surg Pathol. 2005;29:524–33.
47. Miyazaki K, Funakoshi A, Nishihara S, et al. Aberrant insulinoma in the duodenum.
Gastroenterology. 1986;90:1280–5.
48. Adamson AR, Grahame-Smith DG, Bogomoletz V, etal. Malignant argentafnoma with carci-
noid syndrome and hypoglycaemia. Br Med J. 1971;3:93–4.
49. Pelletier G, Cortot A, Launay JM, etal. Serotonin-secreting and insulin-secreting ileal carci-
noid tumor and the use of invitro culture of tumoral cells. Cancer. 1984;54:319–22.
50. Shames JM, Dhurandhar NR, Blackard WG.Insulin-secreting bronchial carcinoid tumor with
widespread metastases. Am J Med. 1968;44:632–7.
51. Kiang DT, Bauer GE, Kennedy BJ.Immunoassayable insulin in carcinoma of the cervix asso-
ciated with hypoglycemia. Cancer. 1973;31:801–5.
52. Ashton MA.Strumal carcinoid of the ovary associated with hyperinsulinaemic hypoglycaemia
and cutaneous melanosis. Histopathology. 1995;27:463–7.
53. Liu TH, Tseng HC, Zhu Y, etal. Insulinoma. An immunohistochemical and morphologic analy-
sis of 95 cases. Cancer. 1985;56:1420–9.
54. Roth J, Klöppel G, Madsen OD, etal. Distribution patterns of proinsulin and insulin in human
insulinomas: an immunohistochemical analysis in 76 tumors. Virchows Arch B Cell Pathol.
1992;63:51–61.
55. Paik WH, Ryu JK, Song BJ, etal. Clinical usefulness of plasma chromogranin a in pancreatic
neuroendocrine neoplasm. J Korean Med Sci. 2013;28:750–4.
56. Vinik AI, Silva MP, Woltering EA, et al. Biochemical testing for neuroendocrine tumors.
Pancreas. 2009;38:876–89.
57. Bajetta E, Ferrari L, Martinetti A, etal. Chromogranin A, neuron specic enolase, carcino-
embryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine
tumors. Cancer. 1999;86:858–65.
58. Oberg K.Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr
Relat Cancer. 2011;18(Suppl 1):S17–25.
59. Anders S. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendo-
crine tumors. Best Pract Res Clin Gastroenterol. 2012;26:803–18.
60. Herwick S, Miller FH, Keppke AL. MRI of islet cell tumors of the pancreas. AJR Am J
Roentgenol. 2006;187:W472–80.
61. Singhi AD, Chu LC, Tatsas AD, etal. Cystic pancreatic neuroendocrine tumors: a clinicopatho-
logic study. Am J Surg Pathol. 2012;36:1666–73.
62. Sundin A, Vullierme MP, Kaltsas G, etal. ENETS consensus guidelines for the standards of care
in neuroendocrine tumors: radiological examinations. Neuroendocrinology. 2009;90:167–83.
63. Caramella C, Dromain C, De Baere T, etal. Endocrine pancreatic tumors: which are the most
useful MRI sequences? Eur Radiol. 2010;20:2618–27.
64. Oberg K.Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao
Paulo). 2012;67:109–12.
65. Joseph S, Wang YZ, Boudreaux JP, etal. Neuroendocrine tumors: current recommendations for
diagnosis and surgical management. Endocrinol Metab Clin N Am. 2011;40:205–31.
66. de Herder WW, Kwekkeboom DJ, Valkema R, etal. Neuroendocrine tumors and somatostatin:
imaging techniques. J Endocrinol Investig. 2005;28:132–6.
67. Garin E, Le Jeune F, Devillers A, etal. Predictive value of 18F-FDG PET and somatostatin recep-
tor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858–64.
68. Binderup T, Knigge U, Loft A, et al. 18F-uorodeoxyglucose positron emission tomog-
raphy predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:
978–85.
69. Gabriel M, Decristoforo C, Kendler D, etal. 68 Ga- DOTA-Tyr3-octreotide PET in neuro-
endocrine tumors: comparison with somatostatin receptor scintigraphy and CT.J Nucl Med.
2007;48:508–18.
9 Pancreatic Neuroendocrine Tumors (pNETs)
70. Naswa N, Sharma P, Kumar A, etal. Gallium-68-DOTANOC PET/CT of patients with gas-
troenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J
Roentgenol. 2011;197:1221–8.
71. Frilling A, Sotiropoulos GC, Li J, etal. Multimodal management of neuroendocrine liver
metastases. HPB (Oxford) 2010;12:361-79. 69. Kim MK.Endoscopic ultrasound in gastroen-
teropancreatic neuroendocrine tumors. Gut Liver. 2012;6:405–10.
72. Atiq M, Bhutani MS, Bektas M, etal. EUS-FNA for pancreatic neuroendocrine tumors: a ter-
tiary cancer center experience. Dig Dis Sci. 2012;57:791–800.
73. Lennon AM, Newman N, Makary MA, etal. EUS-guided tattooing before laparoscopic distal
pancreatic resection (with video). Gastrointest Endosc. 2010;72:1089–94.
74. Fendrich V, Waldmann J, Bartsch DK, Langer P.Surgical management of pancreatic endocrine
tumors. Nat Rev Clin Oncol. 2009;6(7):419–28.
75. Grant CS. Surgical management of malignant islet cell tumors. World J Surg.
1993;17(4):498–503.
76. Grama D, Eriksson B, Martensson H, etal. Clinical characteristics, treatment and survival in
patients with pancreatic tumors causing hormonal syndromes. World J Surg. 1992;16(4):632–9.
77. Crippa S, Zerbi A, Boninsegna L, etal. Surgical management of insulinomas: short- and long-
term outcomes after enucleations and pancreatic resections. Arch Surg. 2012;147(3):261–6.
78. Rothmund M, Angelini L, Brunt LM, etal. Surgery for benign insulinoma: an international
review. World J Surg. 1990;14(3):393–9.
79. Falconi M, Zerbi A, Crippa S, etal. Parenchyma-preserving resections for small nonfunction-
ing pancreatic endocrine tumors. Ann Surg Oncol. 2010;17(6):1621–7.
80. Zhao YP, Zhan HX, Zhang TP, etal. Surgical management of patients with insulinomas: result
of 292 cases in a single institution. J Surg Oncol. 2011;103(2):169–74.
81. Hirshberg B, Libutti SK, Alexander HR, etal. Blind distal pancreatectomy for occult insuli-
noma, an inadvisable procedure. J Am Coll Surg. 2002;194(6):761–4.
82. Norton JA, Shawker TH, Doppman JL, etal. Localization and surgical treatment of occult
insulinomas. Ann Surg. 1990;212(5):615–20.
83. Wolfe MM, Alexander RW, McGuigan JE.Extrapancreatic, extraintestinal gastrinoma: effec-
tive treatment by surgery. N Engl J Med. 1982;306:1533–6.
84. Thompson JC, Lewis BG, Wiener I, etal. The role of surgery in the Zollinger–Ellison syn-
drome. Ann Surg. 1983;197:594–607.
85. Schwarting H, Osse G, Sippel M, etal. Morphometry of the pancreatic islets in patients with
insulinomas and gastrinomas. In: Mutt V, Uvnäs-Moberg K, editors. Regulatory peptides.
Abstracts of the 4th international symposium on gastrointestinal hormones. Amsterdam:
Elsevier; 1983. p.129.
86. Martella EM, Ferraro G, Azzoni C, etal. Pancreatic-polypeptide cell hyperplasia associated
with pancreatic or duodenal gastrinomas. Hum Pathol. 1997;28:149–53.
87. Mallinson CN, Bloom SR, Warin AP, etal. A glucagonoma syndrome. Lancet. 1974;304:1–5.
88. Fujita J, Seino Y, Ishida H, etal. A functional study of a case of glucagonoma exhibiting typical
glucagonoma syndrome. Cancer. 1986;57:860–5.
89. Ruttman E, Klöppel G, Bommer G, etal. Pancreatic glucagonoma with and without syndrome.
Immunocytochemical study of 5 tumour cases and review of the literature. Virchows Arch A
Pathol Anat. 1980;388:51–67.
90. Bordi C, Ravazzola M, Baetens D, etal. A study of glucagonomas by light and electron micros-
copy and immunouorescence. Diabetes. 1979;28:925–36.
91. Hamid QA, Bishop AE, Sikri KL, etal. Immunocytochemical characterization of 10 pancreatic
tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the
pro-glucagon molecule and other neuroendocrine markers. Histopathology. 1986;10:119–33.
92. Trump DL, Livingston JN, Baylin SB. Watery diarrhea syndrome in an adult with
ganglioneuroma- pheochromocytoma: identication of vasoactive intestinal peptide, calcitonin,
and catecholamines and assessment of their biologic activity. Cancer. 1977;40:1526–32.
93. Mendelsohn G, Eggleston JC, Olson JL, etal. Vasoactive intestinal peptide and its relationship
to ganglion cell differentiation in neuroblastic tumors. Lab Investig. 1979;41:144–9.
151
152
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
A. Sanguinetti et al.
94. Capella C, Polak JM, Buffa R, etal. Morphologic patterns and diagnostic criteria of VIP-
producing endocrine tumors. A histologic, histochemical, ultrastructural and biochemical
study of 32 cases. Cancer. 1983;52:1860–74.
95. Udall JN Jr. Diarrhea due to hormone-secreting tumours. In: Lebenthal E, editor. Textbook of
gastroenterology and nutrition in infancy. 2nd ed. NewYork: Raven; 1989. p.1193–205.
96. Long RG, Bryant MG, Mitchell SJ, et al. Clinicopathological study of pancreatic and gan-
glioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas). Br Med J
(Clin Res Ed). 1981;282:1767–71.
97. Verner JV, Morrison AB.Endocrine pancreatic islet disease with diarrhea. Report of a case
due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch
Intern Med. 1974;133:492–9.
98. Tomita T, Kimmel JR, Friesen SR, etal. Pancreatic polypeptide cell hyperplasia with and
without watery diarrhea syndrome. J Surg Oncol. 1980;14:11–20.
99. Ooi A, Kameya T, Tsumuraya M, etal. Pancreatic endocrine tumours associated with WDHA
syndrome. An immunohistochemical and electron microscopic study. Virchows Arch A
Pathol Anat. 1985;405:311–23.
100. Krejs GJ, Orci L, Conlon JM, etal. Somatostatinoma syndrome. Biochemical, morphologic
and clinical features. N Engl J Med. 1979;301:285–92.
101. Vinik AI, Gonzales MR. New and emerging syndromes due to neuroendocrine tumors.
Endocrinol Metab Clin North Am. 2011;40:19–63, vii.
102. Sessa F, Arcidiaco M, Valenti L, etal. Metastatic psammomatous somatostatinoma of the pan-
creas causing severe ketoacedotic diabetes cured by surgery. Endocr Pathol. 1997;8:327–33.
103. Heitz PU, Klöppel G, Polak JM, etal. Ectopic hormone production by endocrine tumors: local-
ization of hormones at the cellular level by immunocytochemistry. Cancer. 1981;48:2029–37.
104. Melmed S, Yamashita S, Kovacs K, etal. Cushing’s syndrome due to ectopic proopiomelano-
cortin gene expression by islet cell carcinoma of the pancreas. Cancer. 1987;59:772–8.
105. Wilander E, El-Salhy M, Willén T, etal. Immunocytochemistry and electron microscopy of an
argentafn endocrine tumor of the pancreas. Virchows Arch A Pathol Anat. 1981;392:263–9.
106. Sano T, Asa SL, Kovacs K.Growth hormone-releasing hormoneproducing tumors: clinical,
biochemical, and morphological manifestations. Endocr Rev. 1988;9:357–73.
107. Bostwick DG, Quan R, Hoffman AR, etal. Growth-hormonereleasing factor immunoreactiv-
ity in human endocrine tumors. Am J Pathol. 1984;117:167–70.
108. Rasbach DA, Hammond JM.Pancreatic islet cell carcinoma with hypercalcemia. Primary
hyperparathyroidism or humoral hypercalcemia of malignancy. Am J Med. 1985;78:337–42.
109. Broadus AE, Mangin M, Ikeda K, etal. Humoral hypercalcemia of cancer. Identication of a
novel parathyroid hormone-like peptide. N Engl J Med. 1988;319:556–63.
110. Saeger W, Schulte HM, Klöppel G.Morphology of a GHRH producing pancreatic islet cell
tumor causing acromegaly. Virchows Arch A Pathol Anat. 1986;409:547–54.
111. Cryer PE, Hill GJ.Pancreatic islet cell carcinoma with hypercalcemia and hypergastrinemia:
response to streptozotocin. Cancer. 1976;38:2217–21.
112. Hammar S, Sale G. Multiple hormone producing islet cell carcinomas of the pancreas. A
morphological and biochemical investigation. Hum Pathol. 1975;6:349–62.
113. Maton PN, Gardner JD, Jensen RT. Cushing’s syndrome in patients with the Zollinger–
Ellison syndrome. N Engl J Med. 1986;315:1–5.
114. Sadoff L, Gordon J, Goldman S.Amelioration of hypoglycemia in a patient with malignant
insulinoma during the development of the ectopic ACTH syndrome. Diabetes. 1975;24:600–3.
115. Wynick D, Williams SJ, Bloom SR.Symptomatic secondary hormone syndromes in patients
with established malignant pancreatic endocrine tumors. N Engl J Med. 1988;319:605–7.
116. Gloor F, Pletscher A, Hardmeier T. Metastasierendes Inselzelladenom des Pankreas mit
5-Hydroxytryptamin- und Insulin-Produktion. Schweiz Med Wochenschr. 1964;94:1476–80.
117. Appleyard TN, Losowsky MS.A pancreatic tumor with carcinoid syndrome and hypoglyce-
mia. Postgrad Med J. 1970;46:159–71.
118. Ohneda A, Otsuki M, Fujiya H, etal. A malignant insulinoma transformed into a gluca-
gonoma syndrome. Diabetes. 1979;28:962–9.
9 Pancreatic Neuroendocrine Tumors (pNETs)
119. Simpson WF, Adams DB, Metcalf JS, et al. Nonfunctioning pancreatic neuroendocrine
tumors presenting as pancreatitis: report of four cases. Pancreas. 1988;3:223–31.
120. Aabo K, Romond E, Dimitrov NV, etal. Pancreatic islet cell carcinoma associated with mul-
tiple hormone secretion and pancytopenia. Evidence of a serum factor suppressing hematopoiesis. Cancer. 1983;51:1691–6.
121. Knifn WD Jr, Spencer SK, Memoli VA, et al. Metastatic islet cell amphicrine carci-
noma of the pancreas. Association with an eosinophilic inltration of the skin. Cancer.
1988;62:1999–204.
122. Feurle GE, Helmstaedter V, Tischbirek K, etal. A multihormonal tumor of the pancreas pro-
ducing neurotensin. Dig Dis Sci. 1981;26:1125–33.
123. Eckhauser FE, Cheung PS, Vinik AI, etal. Nonfunctioning malignant neuroendocrine tumors
of the pancreas. Surgery. 1986;100:978–88.
124. Perrone T, Sibley RK, Rosai J. Duodenal gangliocytic paraganglioma. An immunohisto-
chemical and ultrastructural study and a hypothesis concerning its origin. Am J Surg Pathol.
1985;9:31–41.
125. Parekh JR, Wang SC, Bergsland EK, etal. Lymph node sampling rates and predictors of
nodal metastasis in pancreatic neuroendocrine tumor resections: the ucsf experience with 149
patients. Pancreas. 2012;41(6):840–4.
126. Alumets J, Alm P, Falkmer S, etal. Immunohistochemical evidence of peptide hormones in
endocrine tumors of the rectum. Cancer. 1981;48:2409–15.
127. Kanavaros P, Hoang C, Le Bodic MF, etal. Serotonin-producing pancreatic endocrine tumour.
Histological, ultrastructural and immunohistochemical study of a case. Histol Histopathol.
1990;5:325–8.
128. Padberg B, Schröder S, Capella C, etal. Multiple endocrine neoplasia type 1 (MEN 1) revis-
ited. Virchows Arch. 1995;426:541–8.
129. Samaan NA, Ouais S, Ordóñez NG, etal. Multiple endocrine syndrome type I.Clinical, labo-
ratory ndings, and management in ve families. Cancer. 1989;64:741–52.
130. Duh QY, Hybarger CP, Geist R, etal. Carcinoids associated with multiple endocrine neopla-
sia syndromes. Am J Surg. 1987;154:142–8.
131. Anlauf M, Schlenger R, Perren A, etal. Microadenomatosis of the endocrine pancreas in
patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg
Pathol. 2006;30:560–74.
132. Friesen SR.Tumors of the endocrine pancreas. N Engl J Med. 1982;306:580–90.
133. Le Bodic MF, Heymann MF, Lecomte M, et al. Immunohistochemical study of 100 pan-
creatic tumors in 28 patients with multiple endocrine neoplasia, type I.Am J Surg Pathol.
1996;20:1378–84.
134. Warner TF, Block M, Hafez GR, etal. Glucagonomas. Ultrastructure and immunohistochem-
istry. Cancer. 1983;51:1091–6.
135. Grant CS.Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783–98.
136. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome:
I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes
of Health and comparison with 2229 cases from the literature. Medicine (Baltimore).
2006;85:295–330.
137. Milan SA, Yeo CJ.Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012;24:46–55.
138. van Beek AP, de Haas ER, van Vloten WA, etal. The glucagonoma syndrome and necrolytic
migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.
139. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and
review of nonglucagonomaassociated necrolytic migratory erythema. J Am Acad Dermatol.
1998;38:866–73.
140. Appetecchia M, Ferretti E, Carducci M, etal. Malignant glucagonoma. New options of treat-
ment. J Exp Clin Cancer Res. 2006;25:135–9.
141. Nikou GC, Toubanakis C, Nikolaou P, etal. VIPomas: an update in diagnosis and manage-
ment in a series of 11 patients. Hepato-Gastroenterology. 2005;52:1259–65.
153
154
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
A. Sanguinetti et al.
142. Ghaferi AA, Chojnacki KA, Long WD, etal. Pancreatic VIPomas: subject review and one
institutional experience. J Gastrointest Surg. 2008;12:382–93.
143. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN.Pancreatic insulinoma: current
issues and trends. Hepatobiliary Pancreat Dis Int. 2010;9(3):234–41.
144. Sa Cunha A, Rault A, Beau C, Collet D, Masson B.Laparoscopic central pancreatectomy:
single institution experience of 6 patients. Surgery. 2007;142(3):405–9.
145. Ellison EC, Sparks J, Verducci JS, etal. 50-year appraisal of gastrinoma: recommendations
for staging and treatment. J Am Coll Surg. 2006;202(6):897–905.
146. Norton JA, Fraker DL, Alexander HR, etal. Surgery to cure the Zollinger-Ellison syndrome.
N Engl J Med. 1999;341(9):635–44.
147. Norton JA, Alexander HR, Fraker DL, etal. Does the use of routine duodenotomy (DUODX)
affect rate of cure, development of liver metastases, or survival in patients with ZollingerEllison syndrome? Ann Surg. 2004;239(5):617–26.
148. Panzuto F, Boninsegna L, Fazio N, etal. Metastatic and locally advanced pancreatic endo-
crine carcinomas: analysis of factors associated with disease progression. J Clin Oncol.
2011;29(17):2372–7.
149. Kinoshita K, Minami T, Ohmori Y, Kanayama S, Yoshikawa K, Tsujimura T.Curative resec-
tion of a small cell carcinoma of the pancreas: report of a case of long survival without chemotherapy. J Gastroenterol Hepatol. 2004;19(9):1087–91.
150. Reyes CV, Wang T.Undifferentiated small cell carcinoma of the pancreas: a report of ve
cases. Cancer. 1981;47(10):2500–2.
151. Nilsson O, Van Cutsem E, Delle Fave G, etal. Poorly differentiated carcinomas of the foregut
(gastric, duodenal and pancreatic). Neuroendocrinology. 2007;84(3):212–5.
152. Kolby L, Nilsson O, Ahlman H. Gastroduodenal endocrine tumours. Scand J Surg.
2004;93(4):317–23.
153. Akerstrom G.Management of carcinoid tumors of the stomach, duodenum, and pancreas.
World J Surg. 1996;20(2):173–82.
154. Abu Hilal M, McPhail MJW, Zeidan BA, Jones CE, Johnson CD, Pearce NW.Aggressive
multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth
it? J Pancreas. 2009;10(3):276–9.
155. Norton JA, Kivlen M, Li M, etal. Morbidity and mortality of aggressive resection in patients
with advanced neuroendocrine tumors. Arch Surg. 2003;138(8):859–66.
156. Hellman P, Andersson M, Rastad J, etal. Surgical strategy for large or malignant endocrine
pancreatic tumors. World J Surg. 2000;24(11):1353–60.
157. Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors. Cancer.
2009;115(4):741–51.
158. Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of
neuroendocrine hepatic metastases. HPB. 2010;12(6):427–33.
159. Bruzoni M, Parikh P, Celis R, etal. Management of the primary tumor in patients with meta-
static pancreatic neuroendocrine tumor: a contemporary single-institution review. Am J Surg.
2009;197(3):376–81.
160. Cho CS, Labow DM, Tang L, etal. Histologic grade is correlated with outcome after resec-
tion of hepatic neuroendocrine neoplasms. Cancer. 2008;113(1):126–34.
161. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA.Isolated liver metastases from neu-
roendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187(1):88–92.
162. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK.Hepatic resection for metastatic neu-
roendocrine carcinomas. Am J Surg. 1995;169(1):36–43.
163. Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Fave GD, Falconi M.Role of resection of
the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic
liver disease: a systematic review. Neuroendocrinology. 2011;93(4):223–9.
164. Mayo SC, De Jong MC, Pulitano C, etal. Surgical management of hepatic neuroendocrine
tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol.
2010;17(12):3129–36.
9 Pancreatic Neuroendocrine Tumors (pNETs)
165. Cusati D, Zhang L, Harmsen WS, etal. Metastatic nonfunctioning pancreatic neuroendocrine
carcinoma to liver: surgical treatment and outcomes. J Am Coll Surg. 2012;215(1):117–24.
166. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y.Metastatic endo-
crine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg.
1996;20(7):908–15.
167. Elias D, Lasser P, Ducreux M, etal. Liver resection (and associated extrahepatic resections)
for metastatic welldifferentiated endocrine tumors: a 15-year single center prospective study.
Surgery. 2003;133(4):375–82.
168. Kianmanesh R, Sauvanet A, Hentic O, etal. Two-step surgery for synchronous bilobar liver
metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg.
2008;247(4):659–65.
169. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG.Surgical treatment
of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll
Surg. 2003;197(1):29–37.
170. Thompson GB, Van Heerden JA, Grant CS, Carney JA, Ilstrup DM.Islet cell carcinomas of
the pancreas: a twenty-year experience. Surgery. 1988;104(6):1011–7.
171. Grazi GL, Cescon M, Pierangeli F, etal. Highly aggressive policy of hepatic resections for
neuroendocrine liver metastases. Hepato-Gastroenterology. 2000;47(32):481–6.
172. Bassi C. Middle segment pancreatectomy: a useful tool in the management of pancreatic
neoplasms. J Gastrointest Surg. 2007;11(4):421–4.
173. Hackert T, Hinz U, Fritz S, et al. Enucleation in pancreatic surgery: indications, tech-
nique, and outcome compared to standard pancreatic resections. Langenbeck's Arch Surg.
2011;396:1197–203.
174. Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P.Enucleation of pancreatic
neoplasms. Br J Surg. 2007;94(10):1254–9.
175. Dedieu A, Rault A, Collet D, Masson B, Sa Cunha A.Laparoscopic enucleation of pancreatic
neoplasm. Surg Endosc Other Intervent Tech. 2011;25(2):575–6.
176. DiNorcia J, Lee MK, Reavey PL, etal. One hundred thirty resections for pancreatic neuro-
endocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg. 2010;14(10):1536–46.
177. Assalia A, Gagner M.Laparoscopic pancreatic surgery for islet cell tumors of the pancreas.
World J Surg. 2004;28(12):1239–47.
178. Gagner M, Pomp A, Herrera MF, etal. Early experience with laparoscopic resections of islet
cell tumors. Surgery. 1996;120(6):1051–4.
179. Limongelli P, Belli A, Russo G, etal. Laparoscopic and open surgical treatment of left-sided
pancreatic lesions: clinical outcomes and cost-effectiveness analysis. Surg Endosc Other
Intervent Tech. 2012;26(7):1830–6.
180. Kim SC, Park KT, Hwang JW, etal. Comparative analysis of clinical outcomes for laparo-
scopic distal pancreatic resection and open distal pancreatic resection at a single institution.
Surg Endosc Other Intervent Tech. 2008;22(10):2261–8.
181. Baker MS, Bentrem DJ, Ujiki MB, Stocker S, Talamonti MS.A prospective single institu-
tion comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy.
Surgery. 2009;146(4):635–45.
182. Kooby DA, Hawkins WG, Schmidt CM, etal. Curative laparoscopic resection for pancreatic
neoplasms: a critical analysis from a single institution. J Am Coll Surg. 2010;210(5):779–85.
183. Fernández-Cruz L, Cosa R, Blanco L, Levi S, Lopez-Boado MA, Navarro S.Curative lapa-
roscopic resection for pancreatic neoplasms: a critical analysis from a single institution. J
Gastrointest Surg. 2007;11(12):1607–22.
184. Butturini G, Inama M, Malleo G, etal. Perioperative and long-term results of laparoscopic
spleen-preserving distal pancreatectomy with or without splenic vessels conservation: a retrospective analysis. J Surg Oncol. 2012;105(4):387–92.
185. Singh N, Lo CY, Chan WF.Laparoscopic enucleation of a nonfunctioning neuroendocrine
tumor at the head of the pancreas. JSLS. 2006;10(2):259–62.
155
156
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
A. Sanguinetti et al.
186. Kim SC, Song KB, Jung YS, etal. Short-term clinical outcomes for 100 consecutive cases of
laparoscopic pylorus-preserving pancreatoduodenectomy: improvement with surgical experience. Surg Endosc. 2012;27(1):95–103.
187. Fernandez-Cruz L, Cesar-Borges G.Laparoscopic strategies for resection of insulinomas. J
Gastrointest Surg. 2006;10(5):752–60.
188. Toniato A, Meduri F, Foletto M, Avogaro A, Pelizzo M.Laparoscopic treatment of benign
insulinomas localized in the body and tail of the pancreas: a single-center experience. World
J Surg. 2006;30(10):1916–9.
189. Murakami Y, Uemura K, Sudo T, etal. Number of metastatic lymph nodes, but not lymph
node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am
Coll Surg. 2010;211(2):196–204.
190. Pomianowska E, Westgaard A, Mathisen O, etal. Prognostic relevance of number and ratio
of metastatic lymph nodes in resected pancreatic, ampullary, and distal bile duct carcinomas.
Ann Surg Oncol. 2012;20(1):233–41.
191. Boninsegna L, Panzuto F, Partelli S, et al. Malignant pancreatic neuroendocrine tumour:
lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J
Cancer. 2012;48(11):1608–15.
192. Tomassetti P, Campana D, Piscitelli L, etal. Endocrine pancreatic tumors: factors correlated
with survival. Ann Oncol. 2005;16(11):1806–10.
193. Ouaissi M, Hubert C, Verhelst R, etal. Vascular reconstruction during pancreatoduodenec-
tomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve
cure. World J Surg. 2010;34(11):2648–61.
194. Akatsu T, Aiura K, Shimazu M, etal. Successful pancreatectomy with En-bloc resection of the
celiac artery and portal vein for pancreatic endocrine carcinoma. Hepato-Gastroenterology.
2007;54(76):1269–71.
195. Sakamoto E, Hasegawa H, Ogiso S, etal. Curative resection for a pancreatic endocrine carci-
noma involving the portal vein. Hepato-Gastroenterology. 2004;51(60):1849–51.
196. Norton JA, Harris EJ, Chen Y, etal. Pancreatic endocrine tumors with major vascular abutment,
involvement, or encasement and indication for resection. Arch Surg. 2011;146(6):724–32.
197. Gill GV, Rauf O, MacFarlane IA.Diazoxide treatment for insulinoma: a national UK survey.
Postgrad Med J. 1997;73:640–1.
198. Goode PN, Farndon JR, Anderson J, etal. Diazoxide in the management of patients with
insulinoma. World J Surg. 1986;10:586–92.
199. Vezzosi D, Bennet A, Rochaix P, etal. Octreotide in insulinoma patients: efcacy on hypo-
glycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A
and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757–67.
200. Jensen RT.Peptide therapy. Recent advances in the use of somatostatin and other peptide
receptor agonists and antagonists. In: Lewis JH, Dubois A, editors. Current clinical topics in
gastrointestinal pharmacology. Malden: Blackwell Science, Inc.; 1997. p.144–223.
201. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gas-
tric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology.
2000;118:696–704.
202. Plöckinger U, Wiedenmann B.Neuroendocrine tumors. Biotherapy. Best Pract Res Clin
Endocrinol Metab. 2007;21:145–62.
203. Oberg K, Kvols L, Caplin M, etal. Consensus report on the use of somatostatin analogs for
the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol.
2004;15:966–73.
204. Costa FP, Gumz B, Pasche B.Selecting patients for cytotoxic therapies in gastroenteropan-
creatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:843–54.
205. Öberg K, Knigge U, Kwekkeboom D, etal. Neuroendocrine gastro-entero-pancreatic tumors:
ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2012;23(Suppl 7):vii124–30.
206. Kunz PL, Reidy-Lagunes D, Anthony LB, etal. Consensus guidelines for the management
and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–77.
9 Pancreatic Neuroendocrine Tumors (pNETs)
207. Yao JC, Shah MH, Ito T, etal. Everolimus for advanced pancreatic neuroendocrine tumors.
N Engl J Med. 2011;364:514–23.
208. Raymond E, Dahan L, Raoul JL, etal. Sunitinib malate for the treatment of pancreatic neu-
roendocrine tumors. N Engl J Med. 2011;364:501–13.
209. Yao J, Phan AT.Optimising therapeutic options for patients with advanced pancreatic neuro-
endocrine tumours. Eur Oncol Haematol. 2012;8:217–23.
210. Yao JC, Pavel M, Phan AT, etal. Chromogranin a and neuron-specic enolase as prognostic
markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab.
2011;96:3741–9.
211. Carstens PH, Cressman FK Jr. Malignant oncocytic carcinoid of the pancreas. Ultrastruct
Pathol. 1989;13:69–75.
157
Part III
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Gastrointestinal System
Соседние файлы в папке @xirurgi_2025